ウイルスベクター製造市場レポート：2030年までの動向、予測、競合分析

ウイルスベクター製造の動向と予測

世界のウイルスベクター製造市場は、2024年から2030年までのCAGRが18.7%で、2030年までに推定30億米ドルに達すると予想されます。この市場の主な促進要因は、ウイルスベクターを用いた治療に対する需要の増加、ウイルスベクター製造への投資の増加、ウイルスベクター製造の技術的進歩です。世界のウイルスベクター製造市場の将来は、製薬・バイオ医薬品市場や研究機関市場における機会によって有望視されています。

ウイルスベクター製造市場の洞察

Lucintelは、がん、希少疾患、遺伝性疾患など幅広い疾患の治療に対する細胞・遺伝子治療への需要が高まっていることから、細胞・遺伝子治療が予測期間中に最も高い成長を遂げると予測しています。

この市場の中では、製薬・バイオ製薬企業が、がん、希少疾患、感染症など幅広い疾患に対するウイルスベクターベースの治療法を開発・商業化していることから、製薬・バイオ製薬が最大のセグメントであり続けると思われます。

北米は、同地域の製薬・バイオテクノロジー業界からのウイルスベクターベースの治療薬に対する需要が増加していることから、予測期間中に最も高い成長が見込まれています。

本レポートは、以下の11の主要な質問に回答しています：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のウイルスベクター製造市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のウイルスベクター製造市場の動向（2018～2023年）と予測（2024～2030年）
• タイプ別の世界のウイルスベクター製造市場
  • アデノウイルス
  • レトロウイルス
  • アデノ随伴ウイルス
  • レンチウイルス
  • プラスミドDNA
  • その他
• ワークフロー別の世界のウイルスベクター製造市場
  • アップストリームの製造
  • ダウンストリームの製造
• 用途別の世界のウイルスベクター製造市場
  • 細胞および遺伝子治療
  • ワクチン学
  • 研究およびその他
• 最終用途別の世界のウイルスベクター製造市場
  • 医薬品および生物医薬品
  • 研究機関
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界のウイルスベクター製造市場
• 北米のウイルスベクター製造市場
• 欧州のウイルスベクター製造市場
• アジア太平洋ウイルスベクター製造市場
• その他地域ウイルスベクター製造市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • タイプ別の世界のウイルスベクター製造市場の成長機会
  • ワークフロー別の世界のウイルスベクター製造市場の成長機会
  • 用途別の世界のウイルスベクター製造市場の成長機会
  • 最終用途別の世界のウイルスベクター製造市場の成長機会
  • 地域別の世界のウイルスベクター製造市場の成長機会
• 世界のウイルスベクター製造市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のウイルスベクター製造市場の能力拡大
  • 世界のウイルスベクター製造市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Merck
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen laboratories

Viral Vector Manufacturing Trends and Forecast

The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3.0 billion by 2030 with a CAGR of 18.7% from 2024 to 2030. The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.

A more than 150-page report is developed to help in your business decisions.

Viral Vector Manufacturing by Segment

The study includes a forecast for the global viral vector manufacturing by type, workflow, application, end use, and region.

Viral Vector Manufacturing Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Adenovirus
• Retrovirus
• Adeno-Associated Virus
• Lentivirus
• Plasmid DNA
• Others

Viral Vector Manufacturing Market by Workflow [Shipment Analysis by Value from 2018 to 2030]:

• Upstream Manufacturing
• Downstream Manufacturing

Viral Vector Manufacturing Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Cell & Gene Therapy
• Vaccinology
• Research & Other Applications

Viral Vector Manufacturing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Pharmaceutical & Biopharmaceutical
• Research Institutes
• Others

Viral Vector Manufacturing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Viral Vector Manufacturing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies viral vector manufacturing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the viral vector manufacturing companies profiled in this report include-

• Merck
• Lonza
• Fujifilm Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen Laboratories

Viral Vector Manufacturing Market Insights

Lucintel forecasts that cell and gene therapy is expected to witness highest growth over the forecast period due to growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.

Within this market, pharmaceutical and biopharmaceutical will remain the largest segment due to the fact that these pharmaceutical and biopharmaceutical companies companies are developing and commercializing viral vector-based therapies for a wide range of diseases, including cancer, rare diseases, and infectious diseases.

North America is expected to witness highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Features of the Global Viral Vector Manufacturing Market

Market Size Estimates: Viral vector manufacturing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($B).

Regional Analysis: Viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, workflows, applications, end uses, and regions for the viral vector manufacturing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the viral vector manufacturing market size?

Answer: The global viral vector manufacturing market is expected to reach an estimated $3.0 billion by 2030.

Q.2 What is the growth forecast for viral vector manufacturing market?

Answer: The global viral vector manufacturing market is expected to grow with a CAGR of 18.7% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the viral vector manufacturing market?

Answer: The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing and technological advancements in viral vector manufacturing.

Q4. What are the major segments for viral vector manufacturing market?

Answer: The future of the viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets.

Q5. Who are the key viral vector manufacturing market companies?

Answer: Some of the key viral vector manufacturing companies are as follows:

• Merck
• Lonza
• Fujifilm Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent
• Wuxi Biologics
• Takara Bio
• Waisman Biomanufacturing
• Genezen Laboratories

Q6. Which viral vector manufacturing market segment will be the largest in future?

Answer: Lucintel forecasts that cell and gene therapy is expected to witness highest growth over the forecast period due to growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.

Q7. In viral vector manufacturing market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Viral Vector Manufacturing Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Viral Vector Manufacturing Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Viral Vector Manufacturing Market by Type
  • 3.3.1: Adenovirus
  • 3.3.2: Retrovirus
  • 3.3.3: Adeno-Associated Virus
  • 3.3.4: Lentivirus
  • 3.3.5: Plasmid DNA
  • 3.3.6: Others
• 3.4: Global Viral Vector Manufacturing Market by Workflow
  • 3.4.1: Upstream Manufacturing
  • 3.4.2: Downstream Manufacturing
• 3.5: Global Viral Vector Manufacturing Market by Application
  • 3.5.1: Cell & Gene Therapy
  • 3.5.2: Vaccinology
  • 3.5.3: Research & Other Applications
• 3.6: Global Viral Vector Manufacturing Market by End Use
  • 3.6.1: Pharmaceutical & Biopharmaceutical
  • 3.6.2: Research Institutes
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Viral Vector Manufacturing Market by Region
• 4.2: North American Viral Vector Manufacturing Market
  • 4.2.2: North American Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.3: European Viral Vector Manufacturing Market
  • 4.3.1: European Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.3.2: European Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.4: APAC Viral Vector Manufacturing Market
  • 4.4.1: APAC Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.4.2: APAC Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
• 4.5: ROW Viral Vector Manufacturing Market
  • 4.5.1: ROW Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
  • 4.5.2: ROW Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Viral Vector Manufacturing Market by Type
  • 6.1.2: Growth Opportunities for the Global Viral Vector Manufacturing Market by Workflow
  • 6.1.3: Growth Opportunities for the Global Viral Vector Manufacturing Market by Application
  • 6.1.4: Growth Opportunities for the Global Viral Vector Manufacturing Market by End Use
  • 6.1.5: Growth Opportunities for the Global Viral Vector Manufacturing Market by Region
• 6.2: Emerging Trends in the Global Viral Vector Manufacturing Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Viral Vector Manufacturing Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector Manufacturing Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: Lonza
• 7.3: FUJIFILM Diosynth Biotechnologies
• 7.4: Thermo Fisher Scientific
• 7.5: Cobra Biologics
• 7.6: Catalent
• 7.7: Wuxi Biologics
• 7.8: Takara Bio
• 7.9: Waisman Biomanufacturing
• 7.10: Genezen laboratories